Natural immunomodulator preimplantation factor PIF affected cancer growth in malignant melanomas by Beatrix Kotlan et al.
POSTER PRESENTATION Open Access
Natural immunomodulator preimplantation factor
PIF affected cancer growth in malignant
melanomas
Beatrix Kotlan1,2*, Gyorgy Naszados3, József Továri4,5, János F László6, Maria Godeny3, Eytan R Barnea7,8,9
From Melanoma Bridge meeting 2013
Naples, Italy. 5-8 December 2013
Background and objectives
Malignant and trophoblastic cells share common features
in terms of migration and invasion, while they represent
striking differences also (1). Our results on immune
mechanisms in pregnancy failure (2) and use of immu-
notherapeutics (3) fostered the present new approach:
Pregnancy derived compounds for potential growth con-
trolling effect in metastatic melanomas were studied.
Methods
Preimplantation factor (PIF), a novel peptide secreted by
viable embryos was selected (4), as its immune regula-
tory effects were advantageous (5). Based on our tumor-
immunological project (Ethical permission ETT TUKEB
1642-02/2010), minor tissue samples from surgically
removed lymphnodes of patients with metastatic mela-
nomas were processed. Primary cultures were set up in
special conditions with or without immunomodulatory
PIF. In a parallel system, we transfused human HT199
melanoma cells into immunodeficient NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice and followed
tumor burden in PIF-treated groups.
Results
We found that PIF treatment delayed tumor outgrowth in
time. A tendency of lower tumor volumes was seen both
after administration of immunomodulator peptide and use
of additional physical (static magnetic field) treatment.
A synergistic effect could be achieved by this combination
treatment strategy. Retained or primed expression of
glycolipid based tumorassociated antigens on PIF treated
melanoma cells could be defined by immunofluorescence
FACS and confocal laser microscopy.
Conclusions
Our results suggest an indirect mechanism of PIF on
tumor growth. Retained or enhanced tumor antigen
expression is advantageous, as cancerous cells become
predisposed to be recognized, while induced activation
of antigen presenting cells is beneficial for elimination.
Our complementary strategy resulted as effective and
provides a new potential modality for cancer control.
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